Hi, In our view the evolution of the standard of care for COVID ARDS has served to confirm the target treatment group for a subsequent confirmatory study. It is now apparent that the fail on the primary endpoint of the 300 patient COVID ARDS study was because there is no effective treatment of the age group over 65 with moderate to severe COVID ARDS.It remains to be determined if a higher dose of remestemcel-L may have efficacy in these patients (> 65’s), however, this patient group often has multiple co-morbidities which is likely to lower survival rates.
Recent BP.
Aloha.
Hi, In our view the evolution of the standard of care for COVID...
-
- There are more pages in this discussion • 225 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |